Oncolytic Virus Immunotherapy Market: Trends Report, 2032

Oncolytic Virus Immunotherapy Market – By Virus Type (HSV, Adenovirus, Vaccinia Virus, Reovirus), Application (Melanoma, Breast Cancer, Prostate Cancer), Route of Administration (Intratumoral, Intravenous), End-user – Global Forecast 2024 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600&nbsp;synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Rising incidence of cancer

3.2.1.2&nbsp;&nbsp;&nbsp; Increasing focus towards combination therapies

3.2.1.3&nbsp;&nbsp;&nbsp; Rising R&amp;D investments

3.2.1.4&nbsp;&nbsp;&nbsp; Growing advancements in viral engineering

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp; Development of immunogenicity and resistance to the treatment

3.2.2.2&nbsp;&nbsp;&nbsp; High cost and risk associated with the treatment

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Pipeline analysis

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.7&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategic dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Virus Type, 2021 - 2032 ($ Million)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Herpes simplex virus (HSV)

5.3&nbsp;&nbsp;&nbsp; Adenovirus

5.4&nbsp;&nbsp;&nbsp; Vaccinia virus

5.5&nbsp;&nbsp;&nbsp; Newcastle disease virus

5.6&nbsp;&nbsp;&nbsp; Reovirus

5.7&nbsp;&nbsp;&nbsp; Other virus types

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Million)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Intratumoral

6.3&nbsp;&nbsp;&nbsp; Intravenous

6.4&nbsp;&nbsp;&nbsp; Other routes of administration

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Application, 2021 - 2032 ($ Million)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Melanoma

7.3&nbsp;&nbsp;&nbsp; Breast cancer

7.4&nbsp;&nbsp;&nbsp; Lung cancer

7.5&nbsp;&nbsp;&nbsp; Ovarian cancer

7.6&nbsp;&nbsp;&nbsp; Prostate cancer

7.7&nbsp;&nbsp;&nbsp; Other applications

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Million)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Hospitals &amp; clinics

8.3&nbsp;&nbsp;&nbsp; Cancer research institutes

8.4&nbsp;&nbsp;&nbsp; Ambulatory surgical centers

8.5&nbsp;&nbsp;&nbsp; Other end-users

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

9.1&nbsp;&nbsp;&nbsp; Key trends, by region

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; Japan

9.4.2&nbsp;&nbsp;&nbsp; China

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

9.6&nbsp;&nbsp;&nbsp; Middle East and Africa

9.6.1&nbsp;&nbsp;&nbsp; South Africa

9.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.3&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; Amgen Inc.

10.2&nbsp;&nbsp;&nbsp; Creative Biolabs

10.3&nbsp;&nbsp;&nbsp; Daiichi Sankyo Company Limited

10.4&nbsp;&nbsp;&nbsp; Genelux Corporation

10.5&nbsp;&nbsp;&nbsp; Oncorus Inc.

10.6&nbsp;&nbsp;&nbsp; Replismune Inc.

10.7&nbsp;&nbsp;&nbsp; Siga Technologies

10.8&nbsp;&nbsp;&nbsp; Sorrento Therapeutics Inc.

10.9&nbsp;&nbsp;&nbsp; TILT Biotherapeutics

10.10&nbsp;&nbsp;&nbsp; Viralytics Ltd. 
&nbsp;

Oncolytic Virus Immunotherapy Market

Get a free sample of this report